Skip to main content

Enigma Diagnostics Licenses Roche Patents for PCR-based Dx

NEW YORK (GenomeWeb News) — Enigma Diagnostics has licensed two patents related to PCR technology from Roche Molecular Systems that will allow it to commercialize human and veterinary diagnostic tests worldwide, the company said today.
 
Porton Down, UK-based Enigma said that it has signed a term sheet for two patent licenses for the HybProbe real-time PCR chemistry and to commercialize HybProbe molecular diagnostics for human and animal testing. The company said these technologies complement its existing license for real-time PCR thermal cyclers from Celera Diagnostics. 
 
Enigma is developing a series of multiplexed point-of-care assays for infectious diseases including chlamydia, influenza, and MRSA.
 
Financial terms of the agreement were not released.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.